Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
|Articles|April 26, 2023
Supplements and Featured Publications
- Patient and Payer Considerations in Parkinson Disease Psychosis to Optimize Population Health Outcomes: A Multistakeholder Panel Discussion
Patient and Payer Considerations in Parkinson Disease Psychosis to Optimize Population Health Outcomes: A Multistakeholder Panel Discussion
Advertisement
This publication was sponsored by Acadia Pharmaceuticals Inc.
This clinical brief provides insights from a panel of stakeholders about Parkinson disease (PD) and the prevalence and care of PD psychosis (PDP). The experts also offer key information about PDP from the payer and clinical perspectives.
Advertisement
Related to this article
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
Nicola Hanania, MD, discusses why delayed dupilumab initiation after an asthma exacerbation raises costs and outcomes risk.
Real-world DLBCL data show Incyte’s tafasitamab matches L-MIND responses across diverse Non-Hodgkin lymphoma patients, per Cardinal Health review.
Women with endometriosis have a 46% higher type 2 diabetes risk, highest among premenopausal, non-obese women, study finds.
Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.
AACR urges Congress to protect NIH/NCI funding amid a fight over a contested OMB grantmaking rule.
Mark Belkin, MD, explains why HFpEF goes undiagnosed, how MRA evidence should guide therapy, and what's next for AI-driven care.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 Mutations
4
Designing Effective Value-Based Oncology Models: Lalan Wilfong, MD
5